marked.bio

Company

3D Medicines

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

    Not yet recruiting Phase 2 3D Medicines Started 2026Primary completion 2027-12 NCT05039892

    3D185

    …n Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Alterations

    FGFR2 fusion or rearrangementCholangiocarcinoma,Adult

  2. KN035 for dMMR/MSI-H Advanced Solid Tumors

    Active, not recruiting Phase 2 3D Medicines Started 2018Primary completion 2026-12 NCT03667170

    KN035

    KN035 for dMMR/MSI-H Advanced Solid Tumors

    MSI-H / dMMRSolid Tumor